Musey LK - Search Results

1

Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Ciprero KL, Marchese RD, Richard P, Baudin M, Sterling TM, Manoff SB, Radley D, Stek JE, Soubeyrand B, Grabenstein JD, Samson SI, Musey LK. Ciprero KL, et al. Among authors: musey lk. Hum Vaccin Immunother. 2016 Aug 2;12(8):2135-2141. doi: 10.1080/21645515.2016.1156270. Epub 2016 Mar 22. Hum Vaccin Immunother. 2016. PMID: 27002793 Free PMC article.

2

Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults.

Grabenstein JD, Musey LK. Grabenstein JD, et al. Among authors: musey lk. Vaccine. 2014 May 1;32(21):2399-405. doi: 10.1016/j.vaccine.2014.02.096. Epub 2014 Mar 14. Vaccine. 2014. PMID: 24637174 Review.

3

Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.

Sobanjo-ter Meulen A, Vesikari T, Malacaman EA, Shapiro SA, Dallas MJ, Hoover PA, McFetridge R, Stek JE, Marchese RD, Hartzel J, Watson WJ, Musey LK. Sobanjo-ter Meulen A, et al. Among authors: musey lk. Pediatr Infect Dis J. 2015 Feb;34(2):186-94. doi: 10.1097/INF.0000000000000516. Pediatr Infect Dis J. 2015. PMID: 25741971 Clinical Trial.

4

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.

McFetridge R, Meulen AS, Folkerth SD, Hoekstra JA, Dallas M, Hoover PA, Marchese RD, Zacholski DM, Watson WJ, Stek JE, Hartzel JS, Musey LK. McFetridge R, et al. Among authors: musey lk. Vaccine. 2015 Jun 4;33(24):2793-9. doi: 10.1016/j.vaccine.2015.04.025. Epub 2015 Apr 23. Vaccine. 2015. PMID: 25913828 Clinical Trial.

5

Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.

Ciprero K, Zykov KA, Briko NI, Shekar T, Sterling TM, Bitieva E, Stek JE, Musey L. Ciprero K, et al. Hum Vaccin Immunother. 2016 Aug 2;12(8):2142-2147. doi: 10.1080/21645515.2016.1165373. Epub 2016 May 5. Hum Vaccin Immunother. 2016. PMID: 27149114 Free PMC article. Clinical Trial.

6

Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.

Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, Wang M, Musey L. Kawakami K, et al. Vaccine. 2016 Jul 19;34(33):3875-81. doi: 10.1016/j.vaccine.2016.05.052. Epub 2016 Jun 10. Vaccine. 2016. PMID: 27265450 Free article. Clinical Trial.

7

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.

Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, Musey LK. Ermlich SJ, et al. Among authors: musey lk. Vaccine. 2018 Oct 29;36(45):6875-6882. doi: 10.1016/j.vaccine.2018.03.012. Epub 2018 Mar 17. Vaccine. 2018. PMID: 29559167 Clinical Trial.

8

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.

Kawakami K, Kishino H, Kanazu S, Takahashi K, Iino T, Sawata M, Musey L. Kawakami K, et al. Hum Vaccin Immunother. 2018;14(8):1931-1938. doi: 10.1080/21645515.2018.1456611. Epub 2018 May 14. Hum Vaccin Immunother. 2018. PMID: 29580133 Free PMC article.

9

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, Dallas M, Hartzel J, Marchese RD, Coller BG, Stek JE, Abeygunawardana C, Winters MA, MacNair JE, Pujar NS, Musey L. Greenberg D, et al. Vaccine. 2018 Oct 29;36(45):6883-6891. doi: 10.1016/j.vaccine.2018.02.113. Epub 2018 Sep 21. Vaccine. 2018. PMID: 30244873 Clinical Trial.

10

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK. Peterson JT, et al. Among authors: musey lk. Hum Vaccin Immunother. 2019;15(3):540-548. doi: 10.1080/21645515.2018.1532250. Epub 2018 Nov 14. Hum Vaccin Immunother. 2019. PMID: 30427749 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page